¬K¸`¨¾¬Ì«Å¾É¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¤å/Å@²z¬ì³¯ÂÔ¾ìÅ@²zªø
¡@¡@©N©N©NÃò¡K©N©N©NÃò¡K¬¶¦Ë¤@Án°£Â·³¡Aª÷Âû·Ç³Æ¨Ó³ø³ß¡C«¦¤@¤U¡A106¦~¹A¾ä¬K¸`§Y±N¨Ó¨ì¡A½¤F¤@¤U¹A¥Á¾ä¡A«z..1¤ë¸`®ð¥¿È¤j´H°Ú¡A¤]¦]¬°³o¼Ë®ðÔ¦]¯À¡A¥[¦¨¤F©u¸`©Ê¬y·P¤Î¯f¬r©Ê¸zGª¢µ¥°ª¶Ç¬V©Ê¯e¯f¤§±jŧ¡C
µS°O105¦~¬K¸`´Á¶¡¡A©ñ¤F9¤Ñ¦~°²¡A¦UÆ[¥ú³Ó¦a¡B¦W³Ó¥jÂÝ´X¥G³£¬Oº¡º¡¤H¼é¡A¦b¤H¼é¾ÖÀ½¤Î®ðÔ¼vÅT¤U¡A¨Ï±o¦UÂå°|ªù«æ¶E¡AÃþ¬y·P¯f¨Ò¦Ê¤À¤ñ¹F¨ì°ª®p¡A¸û103¡B104¦~¦P®É´Á¤j´T¤W¤É¡A¤×¨ä¬O¬y·P¨Öµo«¯g®×¨Ò¼Æ¼W¥[¡A¤]Åý³\¦hÂå°|Á^ºò¯«¸g¡B¯h©ó©b©R¡C
¯f¬r©Ê¸zGª¢¤]¤£´q¦hÅý¡A¬K¸`´Á¶¡¡A¨ì³B¹Cª±¡A¦Y³Ü¤U¡A¥¼ª`·N¹ª«²M¼ä©Î²¨©¿½Ã¥Í²ßºD®É¡A´N®e©ö¾ÉP¯fì¶Ç¼½¡C¾Ú¯eºÞ¸p²Îp¸ê®ÆÅã¥Ü¡A102-104¦~¬K¸`´Á¶¡¡A¥§¡¯f¬r©Ê¸zGª¢´N¶E¤H¦¸§¡¤W¸U°_¸õ¡A¤À§O¬°36,175¡B40,938¡B50,683¡A¦]¦¹¡A¥H¤U´N°w¹ï¬y·P¤Î¯f¬r©Ê¸zGª¢¡A¬°¦U¦ì°µÓ²³æ¤¶²Ð:
¤@¡B¬y·P:
´N¬O¬y¦æ©Ê·P«_²ºÙ¡A¨ã¦³©úÅã©u¸`©Ê¯S¼x¡A¥DnP¯f쬰¬y·P¯f¬r¡AÁ{§É¤W©Ò¿×·P«_¡B³ïª¢¡B¤ä®ðºÞª¢¡B¯f¬r©ÊªÍª¢§¡¦³¥i¯à¬°·P¬V¬y·P¯f¬r©Ò¤Þ°_¡C
¶Ç¬V³~®|:¸ªj¤Î±µÄ²¶Ç¬V¡C
¥Dn¯gª¬:µo¿N¡BÀYµh¡B¦Ù¦×µh¡B¯h¡B¬y»ó®÷¡B³ïÄVµh¤Î«y¹Âµ¥¡A³¡¤À¦ñ¦³¸¡Âm¡B¹Ã¦R¡C
¤G¡B¯f¬r©Ê¸zGª¢:
¸zGª¢«Y«üG¡B¤p¸z©Î¤j¸zµoª¢¡A¾ÉP¹Ã¦R©Î¸¡Âm¡C¥xÆW¿Õù¯f¬r¤Î½üª¬¯f¬r¥Dn¬y¦æ©u¸`¬°11¤ë¨ì¹j¦~3¤ë¶¡¡C
¶Ç¬V³~®|: ³z¹LÁT¤f³~®|¡A©Î§l¤J¯f¤H¹Ã¦Rª«¤Î±Æªnª«©Ò²£¥Í¸ªj¡C
¥Dn¯gª¬: ¤ôÂm©M¹Ã¦R¡C¤]¥i¯à¦³ÀYµh¡Bµo¿N¡BGµh¡Bäú¤ß¡B¦Ù¦×»Äµh¡C
¬K¸`´Á¶¡¡A¬°®a®a¹Î¶ê¤§¤é¡A¯f¤H»PªÀ°Ï±µÄ²®É¶¡ÅܱoÀWÁc¡A¤]®e©ö±NªÀ°Ï¥Ø«e¥¿¦b¬y¦æªº¯e¯f±a¦^¯f©Ð¤¤¡A¥B®e©ö¦]¦~Ä֦ѤơB¦Û§Ú·ÓÅU¯à¤O®t¡A¤Î±K¶°©ÊªÅ¶¡¦]¯À¡A¦Ó§Ö³t¶Ç¼½¡A¨ÃÅý¯fµ{©µªø¡A¨ä¹ê³z¹L¤p¤pª`·N¡A¨Æ¥ý¶i¦æ¹w¨¾¡A¬O¥i¥H¦³®Ä±±¨î¶Ç¬V©Ê¯e¯fªºÃzµo:
¦@³qì«h:
1.ª`·N©I§l¹D¤Î«y¹Â§¸`:±j¯P«ØÄ³À¹¤W¤f¸n¡A«OÅ@¦Û¤v¤Î¥L¤H¡C
2.±`¬~¤â:»Ýª`·N¿Õù¤Î¸z¯f¬r¨Ï¥Î°®¬~¤â²G¬OµL®Äªº³á¡C
3.¶¼¹³¡¤À:¤Å¥Í¹¡B¥Í¶¼¡B¤Å¦@¹¡C
4.°·±dºÊ´úºÞ²z:Y±z¾D·P¬V¡AºÉ§Ö´NÂå¡A¦h¥ð®§¡A¤£¤W¯Z¡C
5.¬Ì]±µºØ:±µºØ¬y·P¬Ì]¤£¥Nªí¤£·|·P«_¡A¦ý¥iÁ×§K·P¬V¬y·P«¯g¡A½Ð§â´¤±µºØ¡C
¯f©Ð·ÓÅ@³¡¤À:
1.¸¨¹ê³X«ÈºÞ²z:¨Ó³X®aÄÝY¦³¤W©I§l¹D¯gª¬®É¡A½Ð¥D°Ê´£¨Ñ¤f¸n¡A«ØÄ³¼È½w±´µø©ÎÁYµu·|«È®É¶¡¡C
2.¯f¤H¥~±J¡B¥~¥X©Î¤u§@ªð«Ç«á¡A¸¨¹ê¬~¤â¡AºÊ´ú¦³µL·P¬V¯gª¬¡A©Î¸ß°Ý©Ò¦bÀô¹Ò¦³µL®aÄݩΤu§@¤Hû¦³·P¬V¯gª¬¡C
3.Y¯f¤H¤w¥X²{·P¬V¯gª¬®É¡A¾A·í¹jÂ÷¡A·ÓÅ@¤Hû»ÝÀ¹¤W¨¾Å@¸Ë³Æ¡A¦p¤f¸n©Î¤â®M¡A¹ý©³°õ¦æÀô¹Ò²M¼ä¤Î®ø¬r¡C
¦Ñ¤HÃĨƷÓÅ@²L½Í¡X§ÜÁxÆPÃĪ«¡@¡@¡@¡@¡@¡@¡@¡@¡@¡@¤å/Ãľ¯¬ì¾G¬°¤¸ÃÄ®v
¡@¡@°ªÄ֤ƦѤH¥ÎÃÄȱoÃöª`¡C»OÆW±q1993¦~°_¥¿¦¡ÁÚ¤J°ªÄ֤ƪÀ·|¡]Ageing Society¡^¡A2013¦~12¤ë¡A65·³¥H¤W¤H¤f¶W¹L269¸U¤H¡A¶W¹LÁ`¤H¤fªº11.5¢H¡C¹wp2018¦~65·³¥H¤W¤H¤f±N¹F14¢H¡A¹F¨ì°ê»ÚºD¨Ò©ÒºÙªº°ªÄÖªÀ·|¡]Aged Society¡^¡C±À¦ô¨ì2025¦~¡A»OÆW65·³¥H¤W¤H¤f¬ù20¢H¡AÁÚ¤J¶W°ªÄÖªÀ·|¡]Super Aged Society¡^¡A¥B¦Ñ¤Æ³t«×±N¬°²{¦³¦U¤w¶}µo°ê®a¤¤³Ì§ÖªÌ(¤º¬F³¡²Îp³B¡A2015)¡C
¦Ñ¤H¥Í²z¾÷¯à°I°h¤S¿©±w¦hºØ¯e¯f¦Ñ¤H±`¨Ï¥Î¦hºØÃĪ«¡A·í¥ÎÃĪº¼Æ¥Ø¥Ñ¤@ºØ¼W¥[¦Ü¤GºØ®É¡Aµo¥ÍÃĪ«¤£¨}¨Æ¥óªº¾÷²v·|¼W¥[¬°13%¡FY¨Ï¥Î¤ºØÃĪ«¡Aµo¥ÍÃĪ«¤£¨}¨Æ¥óªº¾÷²v·|¼W¥[¬°58%¡F¤@¥¹¨Ï¥ÎÃĪ«¹F¨ì¤CºØ¥H¤W¡Aµo¥ÍÃĪ«¤£¨}¨Æ¥óªº¾÷²v«h°ª¹F¬°82%(Clyne et al., 2012)¡C¦Ñ¤Hªø¦~(3¦~¥H¤W)°ª¾¯¶q§ÜÁxÆPÃĪ«¼W¥[¤F50-60%¥ÎÃÄ·ÀI¡AªvÀø¤WÀ³À£§C¦Ü³Ì¤Öªº¦³®Ä¾¯¶q(Gray et al., 2015)¡C¦Ñ¤H¹ï§ÜÁxÆPÃĪ«¦³®t²§©Ê¡C¦Ñ¤H¹ï§ÜÁxÆPÃĪ«¤ñ¤@¯ë¤H·P¨ü©Ê§ó¤j¬O¦]¬°¨üpharmacokinetic(¾¯¶q¡A¿@«×)¤Îpharmacodynamic(ÃĮġA§@¥Î¾÷Âà)ªº¦]¯À¦Ó¦³©Ò¤£¦P(de Leon,2011)¡Cì¦]¬O¦Ñ¤H¨xŦ¤ÎµÇŦ¥NÁ¤U°¡A¹ïÃĪ«³q¹LBBB(¦å¸£»Ù½ª)³q³z©Ê¸û°ª(Shi&Klotz, 2011)
§ÜÁxÆPÃĪ«(Anticholinergic drugs)³oÓ¤ÀÃþªºÃĪ«¡A¦bÁ{§É¤Wªº¨Ï¥Î«Ü¼s¤S«ÜÀWÁc(Gerretsen et al., 2011)¡C¦Ñ¤H¦b§Ü¹L±Ó§Ü¼~Æ{¾¯§ÜµjÅË©ÊÃĪ«Beers criteria«ü¥XªvÀø¦Ñ¦~¤H¹L±Ó¤ÏÀ³¡AÀ³Àu¥ý¿ï¥Î¤£¨ã§ÜÁxÆP©Ê½èªº§Ü²Õ´ÓiÃĪ«¡A¦ploratadine (Finska)¡Bcetirizine (Cerin)¡Bfexofenadine (Allegra )¤Îazelastine (Astelin)¡C¨ä¤¤¥H©ö³q¹L¦å¸£»Ù¾Àªº§Ü²Õ´ÓiDiphenhydramine¡A³Ì©ö³y¦¨ÂíÀR»Pºë¯«²V¶Ã¡A¤£À³§@¬°¦w¯vÃĨϥΡC³\¦h¬ã¨s³£«ü¥X¦Ñ¦~¤HÀ³Á×§K¨Ï¥Î¤TÀô§Ü¼~Æ{¾¯¡A¦]¬°¦b¤@¯ëªvÀø¿@«×¤U¨ä§ÜÁxÆP°Æ§@¥Î¤j¡A¨ä¤¤¤S¥H¤T¯ÅÓiµ²ºcªº¤TÀô§Ü¼~Æ{¾¯(¦pamitriptyline (Elavil, Endep)¡Bimipramine (Tofranil)¡Bdoxepin (Sinequan))¸û©ö¹L¦å¸£«Ì½ª¡A¸û±`²£¥Í¤¤¼Ï°Æ§@¥Î(Domenic AC et al., 2004;Lon SS et al., 1994) ¡C»H¯Ö¹L°Ê¯g¡A±`¹B¥Î¤fªA§ÜÁxÆPÃĪ«¡A¦ppropantheline¡Boxybutynin¡Bflavoxate¡Btolterodineµ¥¡A¨ÓªýÂ_»H¯Ö¢§¿¦Ù¤W¤AñQÁxÆP±µ¨ü¾¹¡A´î¤Ö¢§¿¦Ùªº¦¬ÁY±i¤O¦ÓÃP¦¢¡A¨Ã¼W¥[»H¯Ö®e¶q´î¤Ö±Æ§¿¡C¨ä¤¤¥Hpropantheline®ÄªG³Ì¦n¡A¦ý¤]³Ì©ö³y¦¨¦Ñ¦~¤Hºë¯«¯¿¶Ã¡A¨ä¥L³t®Ä«¬§ÜÁxÆPÃĪ««h¥ç³y¦¨¤¤¦Ü««×¤f°®¡BÂíÀR¡A¨Ï¦Ñ¦~¤H¹ï©ó¤j³¡¤Àªº¦Ù¦×ÃP¦¢¾¯©M§ÜµjÅ˾¯@¨ü©Ê¤£¨Î(Shah D et al., 2002)¡A°©Àf¦ÙµjÅ˱`¥ÎÃĤ¤¥Horphenadrine (Norflex)³Ì©ö¤Þ°_§ÜÁxÆP¤ÎÂíÀR°Æ§@¥Î¡A¦Ñ¤Hn·V¥Î¡C
¦Ñ¤H¸û©ö¨Ï¥Î¦hºØÃĪ«¡C¦b¬ü°ê±w¦h«¯e¯fªº²±¦æ²v¬°1.38%¡A¦Ó¨ä¤¤40%¤S¬O¤TºØ©Î¤TºØ¥H¤W¯e¯fªº¦Ñ¤H¡]Remires-Duque et al., 2008)¡C¬ã¨s«ü¥X¦Ñ¤H¦hºØ¯e¯f¾ÉP¦h«¥ÎÃÄ¡A¦Ñ¤H±`¶}¥ßªºÃĪ«ºØÃþ¨Ò¦p:§Ü¼~Æ{ÃÄ¡B§Üºë¯«ÃÄ¡B©¬ª÷´ËÃÄ¡B¦Ù¦×ÃP¦¢¾¯¡B§Ü¹L±ÓÃÄ¡B¨î»Ä¾¯¡B¤î¦R§Ü·wÃÄ¡B¸zG²§±`į°ÊÃÄ¡B»H¯ÖÄáÅ@¸¢¥ÎÃÄ¡A©Ò¶}¥ß³B¤è¤j¦h³£§t¦³§ÜÁxÆP¬¡©Ê(anticholinergic effects)¡B©Ò¥H¦Ñ¤HÃnÅS¦b§ÜÁxÆPÃĪ«·ÀI¤ñ¤@¯ë¤H°ª¡]Bostock et al., 2010)¡C±Nªñ50%ªº¦Ñ¤Hªø´ÁªA¥Î¤@ºØ¥H¤W¦³¼ç¦b¤£·í¥ÎÃĤ§§ÜÁxÆPÃĪ«¡]Fox et al., 2011¡FMaher et al., 2014¡^¡C
¦Ñ¤H¼ç¦b©Ê¤£·í¥ÎÃÄÄY«¡A¨ä¤¤§ÜÁxÆPÃĪ«¼ç¦b¤£¾A·í¥ÎÃÄ(PIADs)¦û¤£¦b¤Ö¼Æ¡C65·³¥H¤Wªºªù¶E¦Ñ¦~¯f¤H¡Aµo²{§t¦³¼ç¦b©Ê¤£¾A·íÃĪ«¤§²±¦æ²v¬°19.1%(Lai et al., 2009)¡C§Q¥ÎPIM-Taiwan¬ã¨sµo²{65·³¥H¤W¦í¥ÁªºPIM(¼ç¦b©Ê¤£¾A·íÃĪ«)²±¦æ²v¬°63.04%¡C¨ä¤¤1¦Ü5ºØ¤£·í¥ÎÃÄ¥e33.34%¡F6¦Ü10ºØ¬°13.11%¡F¤j©ó10ºØ¬°16.59%(Chang et al., 2014)¡C°ê¤º¦Ñ¤H¼ç¦b©Ê¤£¾A·í¥ÎÃIJ±¦æ²v¤j©ó°ê¥~¬GÀ³ÂÔ·V³B¤è¥H½T«O»Ýnªø´ÁªAÃĪººC©Ê¯f¦Ñ¦~¤H°·±d¤Î¥ÎÃĦw¥þ(½²ªF¿«, 2011)¡C¸«í¨} ( 2010)°ê¤º¬ã¨s´£¤Îªù¶E老年¯f±w±µ¨ü»P¶EÂ_µLÃö¤§¡u¼ç¦b不¾A切¥ÎÃÄ¡v³B¤è±¡§Î¡v¥i¥H¬Ý¥X¡A¤j¬ù¦³ªñ¤T¤À¤§¤@(32.47%)ªº老年¯f±w±µ¨ü了¡u¨ã§ÜÁxÆP§@¥Î¤§§Ü²Õ´Ói(Antihistamines with anticholinergic effects)¡v³o類ªº¼ç¦b不¾A切¥ÎÃÄ¡C¥t°ê¤º¬ã¨sµo²{¥xÆW¦Ñ¦~¤H§ÜÁxÆPÃĪ«¼ç¦b¤£¾A·í¥ÎÃÄ(PIADs)¤§³B¤è²±¦æ²v¬°18.67%¡A¦ý¦Ü¤Ö¦³75.65%ªº¦Ñ¦~¤H´¿¸g±µ¨ü¹L¦Ü¤Ö¤@¦¸¤§§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃÄ¡A¦b±±¨î¨ä¥L¬ÛÃö¼vÅT¦]¯À«á¡Aµo²{§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃĪ̬۸û©óµL§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃĪ̡A¨ä«æ¶E¤§¬Û¹ï¦MÀI©Ê¬°1.85¿¡F¦í°|¤§¬Û¹ï¦MÀI©Ê¬°1.07¿(¶À¥úµØ, 2012)¡C°ê¥~¬ã¨sµo²{¦³64%ªº¦Ñ¦~¤H´¿¸g±µ¨ü¹L¦Ü¤Ö¤@¦¸¤§§ÜÁxÆP¼ç¦b¤£¾A·í¥ÎÃÄ(Paul et al., 2015)¡C
¾A®ÉªºÃĨƤ¶¤J½T¹ê¥i´£°ª¦Ñ¤Hªº¥ÎÃĦw¥þ¡A¤×¨ä¬OÁÚ¤J°ªÄÖªºÀø¾i°|¯f¤H¡A¦Ó¥xÆW³B¤è«¬ºA¤Î¥ÎÃÄÀô¹Ò»P°ê¥~¤£¦P¡A¥B¥xÆW¦Ñ¦~¯f±w§ÜÁxÆP¥ÎÃĤ£¾A·í¤§µo¥Í²v¬Û¸û°ê¥~¨Ó±o°ª¡C¦Ó§ÜÁxÆPÃĪ«©Òl¥Í¤§ªvÀø·ÀI¡A½T¹ê¬O¤@Óȱo²`¨sªº°ÝÃD¡C
°Ñ¦Ò¸ê®Æ
Almirall, J., Bolibar, I., Serra-Prat, M., Roig, J., Hospital, I., Carandell, E., . . . Community-Acquired Pneumonia in Catalan Countries Study, G. (2008). New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J, 31(6), 1274-1284.
Chang C-B, Lai H-Y, Yang S-Y, Wu R-S, Liu H-C, Hsu H-Y, et al. (2014) Patient- and Clinic Visit-Related Factors Associated with Potentially Inappropriate Medication Use among Older Home Healthcare Service Recipients. PLoS ONE 9(4): e94350.
Dublin S, Walker RL, Jackson ML et al. Use of opioids or benzodiazepinesand risk of pneumonia in older adults: A population-based case-controlstudy. J Am Geriatr Soc 2011;59:1899¡V1907.
Duran CE, Azermai M, Vander Stichele R. Systematic review of anticholinergicrisk scales in older adults. Response to letter of the editor. Eur J ClinPharmacol 2013;69:1731.
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, Coulton S, Katona C, Boustani MA, Brayne C. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011 ;59(8):1477-83.
Paul, K. J., Walker, R. L., & Dublin, S. (2015). Anticholinergic medications and risk of community-acquired pneumonia in elderly adults: a population-based case-control study. J Am Geriatr Soc, 63(3), 476-485. doi:10.1111/jgs.13327
¸ùÚ¨}. (2010). ¥xÆW¦Ñ¦~¤H¼ç¦b¤£¾A¤Á¥ÎÃÄ»P¼vÅT¦]¯À¤§¬ã¨s. (ºÓ¤h), °ê¥ß¶§©ú¤j¾Ç, ¥x¥_¥«.
¶À¥úµØ(Kuang-Hua Huang)¡B¸â©ÉªÚ(YI- FANG CHAN)¡B¬I§»õ(HUNG-CHE SHIH)¡B§õ«Ø¼ü(CHIEN-YING LEE)*¡ARelationship between Potentially Inappropriate Anticholinergic Drugs (PIADs) and Adverse Outcomes among Elderly Patients in Taiwan¡AJOURNAL OF FOOD AND DRUG ANALYSIS¡A2012 Dec¡A20(4):930-937¡ASCI
- TOP- |
|